Boston Scientific just unveiled a major restructuring plan approved by its board, aiming to slash costs and position the company for future growth — with job cuts on the horizon but new hiring in high-demand areas. The overhaul, set to roll out this year and conclude by 2029, includes supply chain optimization and organizational shifts, with $700M–$800M in pre-tax costs — mostly cash — expected to be spent, while savings will fuel expansion. Investors will watch closely when Q2 earnings drop on July 29, especially regarding performance of its heart device portfolio.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
